Thought Leadership
Legal Opinion: BPCIA is Likely to Survive Latest ACA Challenge
November 11, 2020
Chad Landmon
The Center for Biosimilars

Axinn partner Chad Landmon co-authored The Center for Biosimilars article, "Legal Opinion: BPCIA is Likely to Survive Latest ACA Challenge." 

Click here to access the article.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.